FDA sets July 23–24 hearing on seven research peptides
The FDA’s Pharmacy Compounding Advisory Committee will review BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon for the 503A compounding bulks list.
-
-
FDA proposes excluding semaglutide and tirzepatide from the 503B bulks list
The FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulk substances list. A public comment period is open, closing on or around June 29, 2026.
-
BPC-157 removed from 503A Category 2; compounding status still pending
BPC-157 came off the 503A Category 2 safety-risk list in April 2026 but is not yet on an approved bulks list, leaving its compounding status unresolved ahead of the July PCAC review.
-
Independent lab testing renews scrutiny of research-peptide purity
Third-party analyses report a substantial share of online research peptides miss stated purity, and note that endotoxin can matter even at ~99% purity — reinforcing why COAs are worth reading.
-
GLP-1 research expands: oral Wegovy and ‘beyond GLP-1’ targets
An oral semaglutide 25 mg became available in January 2026, and ADA 2026 featured next-generation “beyond GLP-1” approaches and new mechanism findings.
-
IU vs mL: Why “Units” Are Not a Dose
A unit on an insulin syringe is a volume mark, not an amount of peptide. Why mg/mL is the only valid measurement.